Kreuth V initiative: European consensus proposals for treatment of
haemophilia using standard products, extended half-life coagulation
factor concentrates and non-replacement therapies

Flora Peyvandi, Karin Berger, Rainer Seitz, Anneliese Hilger,
Marie-Laure Hecquet, Michael Wierer, Karl-Heinz Buchheit, Brian O
Mahony, Amanda Bok, Mike Makris, Ulrich Mansmann, Wolfgang
Schramm, and Pier Mannuccio Mannucci

Disclosures: FP reports participation at advisory board of Bioverativ, Roche, Sanofi, Sobi,
Takeda and Grifols. KB has received a Research grant from Roche. RS, AH, MLH, MW,
KHB, BOM, AB, UM have no competing interests to declare. MM has acted as consultant
or participated in advisory panels for Bioverativ, CSL Behring, NovoNordisk and Shire. MM
is also the project leader for EUHASS which receives funding from Bayer, Biotest, BPL,
CSL Behring, Grifols, Kedrion, LFB, NovoNordisk, Octapharma, Pfizer, Roche, Takeda and
Sobi. WS has participated in a DSMB for Biotest and received honoraria for lectures from
Biotest, Novo, Roche, Takeda and Bio&Bio. PMM: Member of the scientific board for the
Bayer Awards. He has also received honoraria from Bayer, Kedrion and Novo Nordisk for
participation at their educational symposia.

Contributions: All authors contributed to the discussion and made the consensus
recommendations. Flora Peyvandi wrote the first draft of the manuscript. All other authors
made intellectual contributions to, reviewed and approved the final manuscript.